Table1 The demographic features in patients with dug induced parkinsonism and their offending drugs.

Patient		Age/sex		Offending drug (duration, month)		Initial H&Y		Follow up H&Y
1		65/F		Levosulpiride (6)		2.5		0
2		69/F		Levosulpiride (10)		2		0
3		71/F		Levosulpiride (5)		2.5		0
4		51/M		Levosulpiride (18)		2		0
5		70/F		Levosulpiride (20)		3		0
6		67/F		Levosulpiride (46)		2.5		0
7		72/M		Levosulpiride (4)		2.5		2.5
8		76/F		Levosulpiride (6)		3		1
9		67/F		Levosulpiride (2)		2		0
10		66/F		Levosulpiride (10)		3		0
11		64/F		Metoclopramide (5)		2.5		0
12		68/M		Perphenazine (120)		3		1
13		73/M		Perphenazine (84)		2.5		0
14		60/F		Perphenazine (26)		2.5		0
15		41/F		Risperidone (5)		5		1
16		68/F		Risperidone (2)		2.5		2
17		65/M		Risperidone (5)		3		0
18		64/F		Chlorpromazine (20)		4		1
19		72/F		Haloperidol (5)		2.5		0
20		66/F		Cilnidipine (12)		2.5		0

H&Y, Hoehn and Yahr stage.